MacroGenics +13.1% on new data from breast cancer study

May 15, 2019 6:53 PM ETMacroGenics, Inc. (MGNX)By: Jason Aycock, SA News Editor1 Comment
  • MacroGenics (NASDAQ:MGNX) is up 13.1% in postmarket trading after the company revealed positive data from its late-stage study of a cancer drug.
  • The results are more data from its Phase 3 SOPHIA study of margetuximab in patients with HER2-positive metastatic breast cancer (who have previously been treated with anti-HER2-targeted therapies).
  • The study met its first sequential primary endpoint of progression-free survival, MacroGenics says.
  • “At ASCO, we will also present data from our Phase 1 study that show HER2-specific T-cell and antibody responses in margetuximab-treated patients," says CEO Scott Koenig. "These data are consistent with the hypothesis that margetuximab facilitates the cooperation of both innate and adaptive immune responses, an emerging paradigm in immuno-oncology.”
  • #ASCO19

Recommended For You

Comments (1)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.